Independent register of U.S. FDA drug recalls · updated Oct 12, 2026
RxRecalls Get alerts

Class II drug recalls - moderate risk

Class II means the product may cause temporary or medically reversible harm, and serious harm is unlikely. It is by far the largest recall class - most potency, dissolution and labeling problems land here.

14,535 recalls, newest first.

Class II · Moderate risk

Clarithromycin Tablets

cGMP Deviations; products being recalled in response to a recall notice from the manufacturer, Wockhardt Limited, following a FDA inspection which noted inadequate investigation of market complaints, resulting in unsuccessful identification of root causes, and the investigation not being expanded to prevent repeat failure

Terminated cGMP deviation Blenheim Pharmacal, Inc. NDC 10544-522-20 D-1110-2015
Class II · Moderate risk

Captopril Tablets

cGMP Deviations; products being recalled in response to a recall notice from the manufacturer, Wockhardt Limited, following a FDA inspection which noted inadequate investigation of market complaints, resulting in unsuccessful identification of root causes, and the investigation not being expanded to prevent repeat failure

Terminated cGMP deviation Blenheim Pharmacal, Inc. NDC 10544-175-30 D-1109-2015
Class II · Moderate risk

CONTRAVE (naltrexone HCl and bupropion HCl)

Failed Tablet/Capsule Specifications: Potential tablet defect of broken tablets and/or equatorial splitting of the bilayer tablets into the two drug components.

Terminated Failed specification Takeda Pharmaceuticals North America, Inc. NDC 64764-890-99 D-1206-2015
Class II · Moderate risk

SUCRETS Sore Throat & Cough Vapor Cherry lozenges

Labeling: Label Mix-Up: An incorrect book label for Sucrets Sore Throat, Cough & Dry Mouth Honey Lemon lozenges was applied to the underside of the Sucrets Sore Throat & Cough Vapor Cherry lozenges tin.

Terminated Labeling / mix-up Medtech Products, Inc. D-1113-2015
Class II · Moderate risk

MD-Gastroview

Labeling: incorrect or missing lot number and/or expiration date

Terminated Labeling / mix-up Mallinckrodt, Inc. NDC 0019-4816-04 D-1132-2015
Class II · Moderate risk

Alprostadil

Lack of Assurance of Sterility; objectionable conditions observed during a FDA inspection

Terminated Sterility / contamination Montana Compounding Pharmacy D-1128-2015

Recalls by year